AU2015359043C1 - Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors - Google Patents

Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors Download PDF

Info

Publication number
AU2015359043C1
AU2015359043C1 AU2015359043A AU2015359043A AU2015359043C1 AU 2015359043 C1 AU2015359043 C1 AU 2015359043C1 AU 2015359043 A AU2015359043 A AU 2015359043A AU 2015359043 A AU2015359043 A AU 2015359043A AU 2015359043 C1 AU2015359043 C1 AU 2015359043C1
Authority
AU
Australia
Prior art keywords
wnt5a
tumor
cells
expression
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015359043A
Other languages
English (en)
Other versions
AU2015359043B2 (en
AU2015359043A1 (en
Inventor
Elena Binda
Angelo Luigi Vescovi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyperstem SA
Original Assignee
HYPERSTEM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HYPERSTEM SA filed Critical HYPERSTEM SA
Publication of AU2015359043A1 publication Critical patent/AU2015359043A1/en
Publication of AU2015359043B2 publication Critical patent/AU2015359043B2/en
Application granted granted Critical
Publication of AU2015359043C1 publication Critical patent/AU2015359043C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015359043A 2014-12-10 2015-12-09 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors Active AU2015359043C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090029P 2014-12-10 2014-12-10
US62/090,029 2014-12-10
PCT/IB2015/002577 WO2016092378A1 (en) 2014-12-10 2015-12-09 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors

Publications (3)

Publication Number Publication Date
AU2015359043A1 AU2015359043A1 (en) 2017-06-29
AU2015359043B2 AU2015359043B2 (en) 2021-09-02
AU2015359043C1 true AU2015359043C1 (en) 2022-01-06

Family

ID=55353245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015359043A Active AU2015359043C1 (en) 2014-12-10 2015-12-09 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors

Country Status (9)

Country Link
US (2) US10688167B2 (enExample)
EP (1) EP3229831B1 (enExample)
JP (1) JP6921755B2 (enExample)
KR (1) KR102674191B1 (enExample)
AU (1) AU2015359043C1 (enExample)
CA (1) CA2970140A1 (enExample)
DK (1) DK3229831T3 (enExample)
ES (1) ES2796973T3 (enExample)
WO (1) WO2016092378A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
ES2796973T3 (es) * 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
CN111417403B (zh) * 2017-10-25 2024-06-04 温特研究公司 Wnt5a肽在减少癌症干细胞中的作用
KR101921836B1 (ko) 2017-11-23 2018-11-26 서울대학교병원 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
WO2019207512A2 (en) * 2018-04-24 2019-10-31 Universidade Do Minho A novel oncogene biomarker, method and uses thereof
EP3613757A1 (en) * 2018-08-20 2020-02-26 Wntresearch AB Solution phase routes for wnt hexapeptides
EP3666789A1 (en) * 2018-12-14 2020-06-17 Wntresearch AB Linear solution phase routes for wnt hexapeptides
CA3137093A1 (en) * 2019-04-16 2020-10-22 Wntresearch Ab Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
CN114081954B (zh) * 2021-10-30 2023-02-28 中国人民解放军陆军军医大学第一附属医院 用于胶质母细胞瘤治疗的药物组合物以及预后的诊断试剂
WO2025088835A1 (ja) * 2023-10-25 2025-05-01 国立大学法人大阪大学 ヒト化抗ｃｋａｐ４抗体又はその抗原結合性断片

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019103A1 (en) * 2008-08-13 2010-02-18 Forskarpatent I Syd Ab The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
AT396872B (de) 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP1226172A1 (en) * 1999-11-05 2002-07-31 Forskarpatent i Syd AB Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
DK2384763T3 (en) * 2005-05-30 2015-07-20 Wntres Ab Peptide ligand for disrupting cancer cell migration
AU2011205409B2 (en) * 2010-01-12 2015-08-20 Oncomed Pharmaceuticals, Inc. Wnt-binding agents and uses thereof
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
PL2726880T3 (pl) * 2011-07-01 2019-09-30 Wntresearch Ab Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty
US20140171356A1 (en) 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
ES2796973T3 (es) * 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019103A1 (en) * 2008-08-13 2010-02-18 Forskarpatent I Syd Ab The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SÄFHOLM ANNETTE ET AL, "The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility", CLINICAL CANCER RESEARCH, 2008, vol. 14, pages 6556 - 6563 *

Also Published As

Publication number Publication date
JP2018500390A (ja) 2018-01-11
EP3229831A1 (en) 2017-10-18
US10688167B2 (en) 2020-06-23
WO2016092378A1 (en) 2016-06-16
EP3229831B1 (en) 2020-03-11
US20200345821A1 (en) 2020-11-05
US20170368158A1 (en) 2017-12-28
DK3229831T3 (da) 2020-06-15
KR20170098861A (ko) 2017-08-30
AU2015359043B2 (en) 2021-09-02
ES2796973T3 (es) 2020-11-30
US11357840B2 (en) 2022-06-14
AU2015359043A1 (en) 2017-06-29
HK1245152A1 (en) 2018-08-24
JP6921755B2 (ja) 2021-08-18
KR102674191B1 (ko) 2024-06-11
CA2970140A1 (en) 2016-06-16
NZ732532A (en) 2024-10-25

Similar Documents

Publication Publication Date Title
US11357840B2 (en) Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
AU2016253149B2 (en) Modulators of ROR1-ROR2 binding
EA023999B1 (ru) Ингибиторы csf-1r для лечения опухолей головного мозга
US20160263187A1 (en) Use of mks inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
US10010581B2 (en) Syndecan peptides and polypeptides and uses thereof
JPWO2012026526A1 (ja) ヘモキニン−１受容体及びヘモキニン−１由来ペプチド
CN113395976A (zh) 良性肿瘤的预防或治疗药
US6972175B2 (en) Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
US20060281670A1 (en) Compositions and methods for modulating angiogenesis
US20130064882A1 (en) Compositions and Methods for the Prevention of Cancer in High Risk Patients
CA3162518A1 (en) Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
EP2515930A1 (en) Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
CN116253775B (zh) 靶向抑制slug转录激活作用的多肽及其用途
HK1245152B (en) Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
US10035833B2 (en) Vascular endothelial growth factor antagonists and methods of making
US10080777B2 (en) Syndecan peptides and polypeptides and uses thereof
US20140296143A1 (en) Angiotensin-(1-7) As A Chemoprevention Agent
CN108314727A (zh) 膜型金属蛋白酶抑制蛋白及其用途
KR20190029328A (ko) 종양 억제 유전자 ｐｉｐ４ｋ２ａ 및 그의 용도

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 SEP 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 09 SEP 2021

FGA Letters patent sealed or granted (standard patent)